Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$14.54 - $21.5 $98,377 - $145,469
-6,766 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$20.24 - $36.01 $136,943 - $243,643
6,766 New
6,766 $140,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $280M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Knott David M Jr Portfolio

Follow Knott David M Jr and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Knott David M Jr, based on Form 13F filings with the SEC.

News

Stay updated on Knott David M Jr with notifications on news.